2026 Interim Report
Filed with HKEX · Stock code 2652 · · 59 pages · English
Summary by 6ix AI
However, the company reported a loss for the period, which reflects challenges in procurement and distribution due to regulatory changes. The management discussion outlines strategies for product commercialization and international expansion moving forward.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CF PharmTech
- Next day disclosure return
- Voluntary announcement ICF004 completes enrolment and dosing of first healthy volunteer in phase i clinical trial
- List of Directors and their Roles and Functions
- Change in board lot size
Later from CF PharmTech
- Voluntary announcement voluntary extension of lock-up period for shares held by core management by six months
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow CF PharmTech into a list and get an email when it puts out news.
Follow CF PharmTech